- Previous Close
27.50 - Open
27.50 - Bid 27.60 x --
- Ask --
- Day's Range
27.50 - 27.60 - 52 Week Range
23.60 - 50.39 - Volume
51 - Avg. Volume
755 - Market Cap (intraday)
188.424M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.85 - Earnings Date May 23, 2025 - May 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. The company offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections. It provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
www.phaarmasia.in35
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: PHRMASI.BO
View MorePerformance Overview: PHRMASI.BO
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHRMASI.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHRMASI.BO
View MoreValuation Measures
Market Cap
187.74M
Enterprise Value
184.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.65
Price/Book (mrq)
1.89
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.01%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
289.28M
Net Income Avi to Common (ttm)
-5.82M
Diluted EPS (ttm)
-0.85
Balance Sheet and Cash Flow
Total Cash (mrq)
3.8M
Total Debt/Equity (mrq)
0.82%
Levered Free Cash Flow (ttm)
--